Efficacy and adverse events of aflibercept, ranibizumab and bevacizumab in age-related macular degeneration: a trade-off analysis.
about
Aflibercept for neovascular age-related macular degenerationEndogenous and Synthetic Cannabinoids as Therapeutics in Retinal DiseaseManagement of Neovascular Age-related Macular Degeneration: A Review on Landmark Randomized Controlled TrialsTreatment of Exudative Age-related Macular Degeneration: Focus on AfliberceptFactors regulating capillary remodeling in a reversible model of inflammatory corneal angiogenesisCost-effectiveness of ranibizumab versus aflibercept in the treatment of visual impairment due to diabetic macular edema: a UK healthcare perspective.A Systematic Review and Meta-Analysis on the Safety of Vascular Endothelial Growth Factor (VEGF) Inhibitors for the Treatment of Retinopathy of Prematurity.Comparison of Outcomes and Costs of Ranibizumab and Aflibercept Treatment in Real-LifeZiv-aflibercept in macular disease.Cost-Effectiveness of Ranibizumab Versus Aflibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion: A UK Healthcare PerspectiveBevacizumab for neovascular age-related macular degeneration in Chinese patients in a clinical setting.Changes in Retinal Nerve Fiber Layer Thickness after Multiple Injections of Novel VEGF Decoy Receptor Conbercept for Various Retinal Diseases.A microarray whole-genome gene expression dataset in a rat model of inflammatory corneal angiogenesis.Targeting the VEGF pathway in metastatic bladder cancer.Safety of monoclonal antibodies and related therapeutic proteins for the treatment of neovascular macular degeneration: addressing outstanding issues.Intravitreal Bevacizumab and Cardiovascular Risk in Patients with Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Randomized Controlled Trials and Observational Studies.Cell-specific biomarkers and targeted biopharmaceuticals for breast cancer treatment.How Well Can Analytic Hierarchy Process be Used to Elicit Individual Preferences? Insights from a Survey in Patients Suffering from Age-Related Macular Degeneration.Comparison of single injection and three monthly injections of intravitreal bevacizumab for macular edema associated with branch retinal vein occlusion.Corneal Neovascularization: A Combined Approach of Bevacizumab and Suramin Showed Increased Antiangiogenic Effect Through Downregulation of BFGF and P2X2.Cost-effectiveness of treating wet age-related macular degeneration at the Kuopio University Hospital in Finland based on a two-eye Markov transition model.Clinical pharmacology of intravitreal anti-VEGF drugs.Intravitreal injection of aflibercept, an anti-VEGF antagonist, down-regulates plasma von Willebrand factor in patients with age-related macular degeneration.[Analysis of cardiovascular diseases after the upload phase with intravitreal ranibizumab and bevacizumab in patients with exudative age-related macular degeneration].Blood coagulation parameters after intravitreal injection of aflibercept in patients with neovascular age-related macular degeneration.The Finnish national guideline for diagnosis, treatment and follow-up of patients with wet age-related macular degeneration.The early effects of intravitreal anti vascular endothelial growth factor agents on intraocular pressure and central corneal thickness.Outcomes and costs of Ranibizumab and Aflibercept treatment in a health-service research context.Three-month outcome of ziv-aflibercept for exudative age-related macular degeneration.The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration-A cost-effectiveness analysis from a societal perspective.The association between myocardial infarction and intravitreal bevacizumab injection.
P2860
Q24186157-3FCBA6F5-7513-4C42-8FCE-2A9448BC1978Q26765576-824A402F-3A90-4467-B418-EEF59DB82E3FQ26767095-6486D7D1-FAB4-4634-8A26-D7681DABEDF4Q26786766-20EF9A4C-EC5F-4E5B-9BED-7F44B404A506Q30804219-F79518D0-E09C-45FD-B9A6-9BFCBF65ED7CQ35592307-A40CAD29-81D7-4865-AB80-746915C2F2A0Q35665701-AB4BBCF0-E314-4E99-AAFD-177EE3543225Q35737573-B776F195-4894-4835-86CA-420181F6BAE2Q35899591-7E693FD8-ED80-47CA-8A6D-A8852904E859Q36526922-974CB604-7F10-4720-A880-02F839F3DBDFQ36832971-712FF1B0-5175-442C-8FA9-15D153FD09B9Q37476086-54C5AC67-513F-41AD-A54D-11126E36690DQ38375654-CC4BD57E-79E8-4691-94E3-2D5A55464A2EQ38534167-77B4B823-BC69-4683-9F42-083514D85220Q38633532-6D136A2A-FA8F-460F-B240-A6A3E0C3ABE1Q38764072-D240A23B-C53B-48BB-9994-3C024AF0864AQ38852051-2031083D-3199-4EDC-A789-869583229F0AQ39714255-25893DCE-CE18-4CEE-BAEA-2DDECDAE2F99Q43129563-FFBA2626-213B-48E0-A9CB-5726F46F73BEQ47266557-E6C7B00E-8B95-456C-BB53-980D69BB4509Q47661928-1CD2291D-11C8-49DA-B971-D0A7DF9D22B7Q48109878-0C994070-479C-4095-86A9-41A640AD4811Q48171768-4522113B-9727-485A-AB3A-4A5F9B830A34Q48747309-066B618B-BF1A-49F2-8296-AA4D276EF54DQ50062366-CA806D94-FB2F-47CF-8C82-0BE50C39D677Q50903375-3C2D3813-D6FB-4FDA-BBA1-F454D6D78214Q50941185-B6E62F78-929E-46B1-9290-E5BF48683055Q51410130-862B19DD-A211-4271-B2EE-AC2D9F5ADDCAQ53134473-7BBA8ACF-47A9-4FF0-A0B5-745C9F835A41Q54969941-F8166430-0A24-4C27-863B-57BB4F77F1BCQ55122457-C5D8D887-A390-4235-8D1C-6CC77D515044
P2860
Efficacy and adverse events of aflibercept, ranibizumab and bevacizumab in age-related macular degeneration: a trade-off analysis.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Efficacy and adverse events of ...... eration: a trade-off analysis.
@ast
Efficacy and adverse events of ...... eration: a trade-off analysis.
@en
type
label
Efficacy and adverse events of ...... eration: a trade-off analysis.
@ast
Efficacy and adverse events of ...... eration: a trade-off analysis.
@en
prefLabel
Efficacy and adverse events of ...... eration: a trade-off analysis.
@ast
Efficacy and adverse events of ...... eration: a trade-off analysis.
@en
P2093
P1476
Efficacy and adverse events of ...... eration: a trade-off analysis.
@en
P2093
Alfons G Kessels
Lucas M Bachmann
Martin K Schmid
Michael A Thiel
Oliver M Job
P304
P356
10.1136/BJOPHTHALMOL-2014-305149
P407
P577
2014-06-11T00:00:00Z